
Sign up to save your podcasts
Or


Paul Hagerman discusses a Review which highlights the latest clinical and molecular understanding of the FMR1 mutation and FXTAS.
By The Lancet NeurologyPaul Hagerman discusses a Review which highlights the latest clinical and molecular understanding of the FMR1 mutation and FXTAS.

43,687 Listeners

299 Listeners

503 Listeners

53 Listeners

113,121 Listeners

94 Listeners

518 Listeners

189 Listeners

59 Listeners

80 Listeners

0 Listeners